• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·002620.KS
Share

Jeil Pharma Holdings Inc Stocks

₩ 7280Last Updated 16.10.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

₩ 86.93M

₩ 7280
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Jeil Pharma Holdings Inc. is a South Korean pharmaceutical enterprise focused on the production and sale of active pharmaceutical ingredients (APIs), incrementally modified drugs (IMDs), and generic pharmaceuticals. The company's comprehensive API portfolio encompasses a variety of therapeutic areas, including antimicrobials, gastrointestinal remedies, cardiovascular medications, neuropsychiatric treatments, oncology drugs, endocrinology products, urology solutions, antivirals, and antihistamines, in addition to transdermal patch formulations. Furthermore, Jeil Pharma Holdings offers a broad selection of finished dosage forms addressing conditions such as bacterial, fungal, and viral infections; cardiovascular and endocrine disorders; neurological and gastrointestinal ailments; urological and oncological diseases. Its extensive range also features antihistamines, rheumatology, respiratory, otolaryngological, hepatic, and purgative agents. With a global presence, Jeil Pharma Holdings Inc. exports its products to approximately 40 countries, spanning regions like Southeast Asia, Central and South America, and Africa. Founded in 1959, the company's headquarters are situated in Seoul, South Korea.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.10.2026 21:12

DeepSeek unveils updated AI model claimed to be faster than its predecessor

17.10.2026 16:01

Small caps last week: Russell 2000 correction, Bumble sale, Crocs celeb partnerships

17.10.2026 13:01

The Weak Link in the AI Revolution: Big Pharma Comes to the Rescue of Investors; Burry Believes in Mortgages

17.10.2026 03:47

‘All of this is going to pass’: Nvidia CEO is confident AI rally will continue

17.10.2026 03:37

"Musk Magic" Is Back: CFRA Analyst Raises Tesla's Price Target Due to the Flying Car

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026